Acute Coronary Syndrome (ACS)

Researchers are evaluating erectile function changes in male patients who undergo percutaneous coronary intervention PCI for either a heart attack or stable angina. The study aims to understand how myocardial infarction affects erectile function over time and to explore whether erectile dysfunction can predict future cardiac events. This observational study compares erectile function between patients with myocardial infarction and those with stable angina using standardized questionnaires. Participants are grouped into two sets those treated with PCI after a heart attack and those treated due to stable angina. Erectile function is assessed at baseline after recovery from PCI, and at 3 and 6 months post-procedure using the International Index of Erectile Function IIEF questionnaire. Additional assessments include the Beck Depression Inventory and Fear of Cardiac Recurrence and Progression Scale. Researchers also collect clinical data such as cardiac vessel scores, ejection fraction, testosterone levels, body measurements, medication use, and the intervention method. During the study, male participants aged 30 to 75 will complete face-to-face interviews and questionnaires at specified intervals baseline, 3 months, and 6 months after PCI. The study measures changes in erectile function scores over time and examines associations with cardiac health, depression, and anxiety symptoms. Safety and participation are monitored throughout the follow-up period. The total duration of involvement is up to 6 months, with evaluations focusing on erectile function and related health parameters.

Researchers are evaluating two strategies for optimizing stent implantation during bifurcation stenting of the left main coronary artery LM in patients with coronary artery disease. This prospective, randomized, controlled trial compares an intravascular ultrasound IVUS-guided approach versus an IVUS-trained eye approach based on angiographic assessment and operator experience. The study aims to determine whether an angiography-based method performed by experienced physicians is non-inferior to the IVUS-guided technique regarding stent placement quality and planimetric characteristics immediately after the procedure. All patients receive the same type of coronary stent Calypso, R-Vascular, Russia to reduce variability. The IVUS-guided group undergoes baseline IVUS assessment to select and optimize stent placement with mandatory steps like kissing balloon dilation and proximal optimization. The angiography-guided group relies on visual angiographic evaluation for stent and balloon selection, with IVUS used only after the procedure to assess stent results. Both groups follow the same optimization steps and procedural techniques. Participants are monitored immediately after the procedure with IVUS imaging to measure stent expansion and quality. Follow-up assessments occur up to one year post-procedure to evaluate device-oriented composite endpoints. The study includes detailed procedural steps, imaging, and clinical outcome tracking to compare the two approaches. Total participation lasts through the intervention and one year of follow-up to assess safety and effectiveness outcomes.

Researchers are studying patients with elevated Lipoproteina levels above 30 mgdL who have undergone percutaneous coronary intervention PCI with drug-eluting stent DES implantation but have not experienced cardiovascular events or significant bleeding within 12 months after the procedure. The trial aims to compare whether extending dual antiplatelet therapy DAPT from the standard 12 months to 24 months can reduce major adverse cardiovascular and cerebrovascular events such as death, heart attack, and stroke. This randomized, double-blind trial also evaluates if longer DAPT is as safe as the standard duration regarding bleeding and net adverse clinical events. Participants are randomly assigned to one of two groups one group receives aspirin combined with clopidogrel for 24 months after PCI, while the other group receives aspirin plus a placebo identical to clopidogrel for 12 months. The therapy is delivered as oral medications daily. The study includes a follow-up period with assessments at 3, 6, 9, and 12 months after randomization to monitor outcomes. The trial is conducted across multiple centers with blinded evaluation of results. During the study, participants will undergo regular monitoring to assess cardiovascular events and bleeding incidents, including all-cause death, myocardial infarction, stroke, stent thrombosis, and various bleeding types classified by the Bleeding Academic Research Consortium. Data will be collected through clinical visits and evaluations at predefined intervals up to 12 months after randomization. The research team will analyze these measures to determine the efficacy and safety of extended DAPT in this high-risk population. The total study duration includes treatment and follow-up phases to ensure comprehensive outcome assessment.

Researchers are evaluating the accuracy of myocardial imaging using integrated 18F-FDG PETMR to detect viable heart muscle in patients with ischemic heart disease. The study also aims to see if this imaging method can replace the current standard that combines 18F-FDG PET with 99mTc MIBI SPECTCT gated myocardial perfusion imaging. This is important as assessing heart muscle viability helps predict treatment success and select the best surgical options, especially before coronary artery bypass grafting CABG. Participants will undergo two procedures within two weeks before surgery an integrated 18F-FDG PETMR scan, and a combined 18F-FDG PETMR plus 99mTc MIBI gated myocardial perfusion imaging. These imaging techniques allow doctors to evaluate heart blood flow, metabolism, muscle vitality, and function simultaneously. The study focuses on patients with significant coronary artery narrowing and reduced heart function, some of whom may also receive stem cell treatments alongside CABG. During the study, participants will sign informed consent and complete the imaging scans, with outcome measures including myocardial perfusion and metabolic imaging assessed approximately two days after the scans. Researchers will monitor heart function and muscle viability to help determine surgical outcomes. The study runs until 2026 and involves adults under 80 years with specific heart conditions, ensuring comprehensive assessments to support future heart disease treatments.

Researchers are studying patients with acute coronary syndrome who undergo percutaneous coronary intervention to understand the risk factors that affect the occurrence and prognosis of this condition. This observational study will follow participants for at least two years to track major adverse cardiovascular events, including all-cause mortality, cardiovascular mortality, and ischemic stroke. The study is led by Su Guohai and aims to gather comprehensive data to improve knowledge about acute coronary syndrome outcomes. Participants will have blood and fecal samples collected for detailed analysis. Clinical information such as diagnosis, medical history, lab test results, treatment methods, prognosis, and follow-up data will also be recorded. The study focuses on monitoring the progression and outcomes of acute coronary syndrome over time through regular data collection. During the study, participants will be closely followed up to document any major cardiovascular events over a two-year period and beyond. Researchers will assess various health measures and risk factors to better understand how acute coronary syndrome develops and progresses. The total duration of participation includes initial enrollment and ongoing observation to capture long-term outcomes.

Researchers are evaluating the potential benefits of implanting an implantable cardioverter defibrillator ICD in patients with coronary artery disease who have survived cardiac arrest caused by ventricular fibrillation or sustained ventricular tachycardia. These patients have undergone complete revascularization and have a left ventricular ejection fraction LVEF above 35%. The study aims to assess whether ICD implantation can improve survival outcomes compared to standard medical therapy. Participants are randomly assigned to one of two groups one group receives an ICD implanted either during admission or within 4 weeks after discharge from the initial cardiac event, while the other group receives guideline-directed medical therapy without ICD implantation. The study compares these approaches to understand the effect of ICDs on survival in this patient population. During the study, participants will be monitored for outcomes including all-cause mortality over a five-year period, as well as mortality related to cardiovascular causes at one year. Researchers will collect data on sudden cardiovascular death and cardiovascular death within the first year. The trial includes follow-up assessments to track these outcomes and the overall health of participants throughout the study duration.

This research aims to learn more about vitamin C deficiency in patients with either acute or chronic diseases. It focuses on understanding how symptoms change over time and how well patients tolerate treatment. The study involves patients diagnosed with vitamin C deficiency either by lab tests or based on symptoms such as fatigue, infections, bleeding gums, joint pain, and poor wound healing. The study observes patients treated with Vitamin C Injektopas 7.5 g, given for an expected average of about 3 weeks for acute diseases or 12 weeks for chronic diseases. Two groups are included those with acute underlying diseases and those with chronic underlying diseases, both receiving this vitamin C therapy during the study period. Participants will be followed to assess changes in general and disease-specific symptoms, as well as treatment tolerability and overall effectiveness from the patients perspective. Researchers will also record the number of vitamin C infusions and measure quality of life for chronic disease patients. The study duration ranges up to approximately 12 weeks, with evaluations at the last visit to understand symptom improvement and treatment impact.

Researchers are evaluating a predictive tool called the Multifactorial Dynamic Perfusion Index MDPI to estimate the risk of acute kidney injury after cardiac surgery involving cardiopulmonary bypass CPB. This observational study involves adults and infants undergoing cardiac surgery, aiming to validate the MDPI in adults, develop a version for infants under 20 kg, and explore if the MDPI can predict other complications including mortality. The MDPI combines seven variables measured during CPB, many of which can be modified by the surgical team to potentially improve patient outcomes. The study is divided into three parts first, validating the MDPI in 800 adult cardiac surgery patients from two centers using existing CPB monitors that collect data such as hematocrit, oxygen delivery, arterial pressure, and transfusions second, developing a modified MDPI for 200 infants under 20 kg undergoing congenital heart surgery with additional infant-specific variables and third, investigating whether the MDPI can predict other postoperative issues like low cardiac output, longer ICU stays, bleeding complications, and 30-day mortality. Data collection includes parameters recorded during surgery and postoperative creatinine values. Participants will undergo cardiac surgery with CPB, during which relevant physiological data will be continuously recorded by specialized monitors. After surgery, kidney function and other outcomes will be monitored for up to 48 hours, with extended follow-up for complications and mortality over 30 days. Researchers will analyze how well the MDPI predicts acute kidney injury and other clinical outcomes, aiming to incorporate the MDPI into real-time monitoring devices to guide therapeutic decisions during surgery.

Researchers are conducting a multi-center clinical study to assess artificial intelligence AI algorithms for measuring heart function and size using echocardiography. The study aims to compare AI measurements with those of physicians at different experience levels, evaluate the accuracy and stability of AI, and explore its use in complex heart conditions like cardiomyopathy, valve disease, and coronary heart disease. The goal is to improve diagnostic consistency and clinical workflows across medical centers. The study involves measuring cardiac chamber size and function in 1600 participants using AI, senior physicians, and intermediate physicians. All measurements are made with Mindray ultrasonic machines. AI and intermediate physician results are completed within one day after data collection, while senior physician results are completed within one month. The study will establish a standardized reference system for AI-assisted echocardiographic measurements and evaluate AIs performance in special cases. Participants will undergo echocardiographic scans with measurements of left and right ventricular size and function, Doppler ultrasound indicators, and valve annulus displacements. Researchers will analyze data to compare AI and physician measurements, assess measurement deviations, and evaluate AIs efficiency in reducing analysis time. The study will run until July 2026, with ongoing data collection and analysis across multiple centers, aiming to promote wider clinical application of AI technology for cardiovascular disease diagnosis.

This research aims to observe patients who participated in the EXCELLENT clinical trial for acute myocardial infarction. It focuses on comparing long-term clinical outcomes between those who received standard care and those treated with ProtheraCytes. The study is designed to follow these patients for up to 10 years to gather valuable safety and efficacy data. Participants include those from both the standard of care group and the ProtheraCytes treatment group who have completed their 6-month follow-up in the original EXCELLENT trial. This observational study involves collecting data without additional interventions or treatments. The study duration spans an average of 10 years from the initial randomization in the EXCELLENT trial. During the study, researchers will monitor participants regularly to assess safety and treatment outcomes over the long term. Data collection includes clinical evaluations and tracking of any health changes. The study does not involve new treatments but focuses on observing and comparing patient progress. Participants will continue their usual care outside the study, and their safety will be monitored throughout.